PDS Biotechnology Corp (NASDAQ:PDSB)

6.26
Delayed Data
As of 4:00pm ET
 -0.15 / -2.34%
Today’s Change
2.52
Today|||52-Week Range
17.85
-22.72%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$192.5M

Company Description

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.

Contact Information

PDS Biotechnology Corp.
Florham Park
Princeton New Jersey 07932
P:(800) 208-3343
Investor Relations:
(908) 517-3613

Employees

Shareholders

Individual stakeholders7.51%
Mutual fund holders7.43%
Other institutional15.38%

Top Executives

Frank K. Bedu-AddoPresident, Chief Executive Officer & Director
Matthew C. HillChief Financial & Accounting Officer
Gregory L. ConnChief Medical Officer
Joe J. DervanVice President-Research & Development
Janetta TrochimiukChief Accounting Officer & Controller